Accession Number:

ADA218936

Title:

The Mechanism of Action of Ribavirin on Bunyavirus Infected Cells

Descriptive Note:

Midterm rept. 1 Aug 1987-31 Jan 1989,

Corporate Author:

CHILDREN'S HOSPITAL CORP BOSTON MA

Personal Author(s):

Report Date:

1989-03-03

Pagination or Media Count:

13.0

Abstract:

Ribavirin 1-B-D-ribofuranosyl-1-1,2,4-triazole-3-carboxamide or Virazole is a broad-spectrum antiviral agent whose molecular mode of action remains remarkably controversial. The drug was approved by the Food and Drug Administration in 1986 for aerosol use in infants with serious infections due to respiratory syncytial virus RS. Ribavirin is and has been under clinical investigation against a variety of viral illness, including those due to influenza virus, Lassa fever, Korean hemorrhagic fever with renal syndrome KHFS and Human immunodeficiency virus HIV. There has been a great deal of clinical interest in utilizing ribavirin for HIV infections. It has been reported to slow the development of AIDS in HIV infected patients McCormick et al., 1984. We describe here the reported mechanisms of action of this newly licensed drug. jg

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE